Crucell: A Global Perspective

Global facilities

Technology Research Development Manufacturing Sales & Marketing
Netherlands HQ Netherlands Netherlands Netherlands Netherlands (Benelux)
Switzerland Switzerland Switzerland Switzerland Switzerland
U.S.* U.S.* Sweden Korea Korea
      Sweden Sweden (Nordic)
      Spain Spain
        Argentina
        China
        Indonesia
        Italy
        Vietnam
        Canada
        U.S.

* PERCIVIA, a Joint Venture with DSM Biologics

Map of Sales & Marketing and Manufacturing distribution worldwide 60 - We sell our vaccines in 60 countries which makes us the largest independent vaccine player worldwide. We license proprietary technolgies to the biopharma market

Products

Our vaccine business provides stable and predictable sales and cash flow. We are the largest independent vaccine player, selling our vaccines in 60 countries. Within vaccines we operate in three main markets: paediatric, travel and endemic, and respiratory.

Pipeline

We have a number of programs in various stages of development. Most of these are based on Crucell’s innovative PER.C6® technology.

Technologies

We have five core technologies; of which PER.C6® technology is Crucell’s core proprietary technology. With over 60 commercial licenses issued on PER.C6® technology, Crucell has set new industry standards for the development and industrial-scale manufacturing of vaccines, recombinant proteins including monoclonal antibodies, and gene therapy products.

Products

Paediatric

Quinvaxem® a vaccine against five important childhood diseases.

Epaxal® Junior an aluminum–free hepatitis A vaccine for children.

Hepavax–Gene® a vaccine against hepatitis B.

MoRu–Viraten® a vaccine against measles and rubella.

Travel and endemic

Epaxal® the only aluminum–free hepatitis A vaccine.

Vivotif® the only oral typhoid vaccine.

Dukoral® the only oral cholera vaccine.

Respiratory

Inflexal®V an influenza vaccine.

Click here for more details

Research & Development Pipeline

  • Influenza vaccines, for both seasonal and pandemic flu.
  • Tuberculosis vaccine
  • Rabies monoclonal antibody cocktail
  • Malaria vaccine
  • Ebola vaccine
  • HIV vaccine
  • Yellow fever vaccine
Click here for more details

Technologies

PER.C6® human designer cell line for the development and large–scale manufacturing of biopharma products.

AdVac® used in combination with PER.C6®, to develop recombinant vaccines.

MAbstract® applied for discovery of novel drug targets and identification of human antibodies.

STAR® designed to enhance production yields of recombinant human antibodies and proteins on mammalian cell lines.

Virosome a vehicle enabling the use of virus antigens in the making of vaccines.

Click here for more details

Back to top ↑